A human innovation company.
Brighter addresses common public health challenges through a group of innovation companies. By introducing groundbreaking technology and innovative services, we aim to improve health outcomes and wellbeing amongst the global population and facilitate increased efficiency throughout the healthcare system. Currently the group has offices in Stockholm, Dubai and Jakarta. Brighter’s shares are listed on Nasdaq First North Growth Market (“BRIG”).
Tackling diabetes first.
We are currently focused on addressing the global diabetes epidemic, introducing Actiste® Diabetes Management as a Service. Diabetes is one of the world’s fastest-growing chronic conditions, affecting more than 463 million adults worldwide, with the number set to rise to 700 million by 2045.
Diabetes must be monitored daily, as the condition can lead to a wide range of serious health complications. In addition to the personal suffering it causes, diabetes also represents a massive financial cost and places a huge burden on healthcare systems – at least USD 760 billion dollars in health expenditure in 2019 (10% of total spending on adults). Currently 374 million people are at increased risk of developing type 2 diabetes.
(Data from IDF Diabetes Atlas Ninth edition 2019)
Data-driven diabetes care.
The trend in diabetes care is to provide patients with ways to better manage their own treatment, and thereby ease the burden on healthcare systems. We have created Actiste – Diabetes Management as a Service to meet this global need. Read all about it here.
While Actiste is our current focus, we believe the health data generated through this area and other initiatives we are involved in will provide a solid base for further business opportunities in clinical care and research.